Bupropion HCl 75 mg Does Not Require Tapering for Discontinuation
For patients on bupropion HCl 75 mg once daily, you can discontinue the medication abruptly without tapering. This low dose is well below the threshold where gradual dose reduction is recommended.
Why No Taper is Needed at 75 mg
The FDA-approved prescribing information for bupropion HCl extended-release specifically addresses tapering only for patients on 300 mg daily doses 1. The guidance states: "When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation" 1.
Since your patient is already at 75 mg—half the dose at which tapering begins—no further dose reduction is necessary before stopping.
Key Clinical Considerations
Bupropion's Unique Pharmacology
- Bupropion is a dopamine/norepinephrine reuptake inhibitor, not a serotonin reuptake inhibitor 2
- It has a biphasic elimination with a redistribution half-life of approximately 1.5 hours and an elimination half-life of 14 hours 3
- Unlike SSRIs/SNRIs, bupropion does not typically cause significant withdrawal syndromes when discontinued
When Tapering IS Recommended
The only scenario where bupropion tapering is explicitly recommended is:
- Patients on 300 mg daily: Reduce to 150 mg once daily, then discontinue 1
- This applies to both Major Depressive Disorder and Seasonal Affective Disorder indications
Monitoring After Discontinuation
While abrupt discontinuation at 75 mg is safe, monitor for:
- Neuropsychiatric symptoms: Although uncommon, watch for emergence of depression, anxiety, or mood changes 4
- Return of underlying symptoms: If treating depression, ensure appropriate follow-up for potential relapse
- Seizure risk normalization: Bupropion lowers seizure threshold; this risk resolves after discontinuation 4
Common Pitfall to Avoid
Do not apply SSRI/SNRI tapering principles to bupropion. Recent evidence emphasizes the importance of hyperbolic, gradual tapers for serotonergic antidepressants to avoid withdrawal symptoms 5, 6, 7. However, bupropion's distinct mechanism (dopamine/norepinephrine vs. serotonin) means it does not carry the same withdrawal risk profile. The alternate-day dosing strategy sometimes used for SSRIs would be inappropriate and unnecessary for bupropion at this dose 5.
Practical Implementation
For a patient on bupropion HCl 75 mg once daily:
- Simply stop the medication after the last dose
- Schedule follow-up within 2-4 weeks to assess for symptom recurrence
- Counsel the patient that they may notice return of original symptoms (if treating depression/SAD) but should not expect withdrawal effects
- Document the indication for which bupropion was prescribed to guide monitoring
The evidence is clear: at 75 mg daily, no tapering schedule is needed—just discontinue.